Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2016 Financial Results

Go back to Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2016 Financial Results

Maxim Positive on Onconova Therapeutics (ONTX) Following Q2 Report; Notes Accelerating INSPIRE Enrollment

August 15, 2016 2:53 PM EDT

Maxim affirms Onconova Therapeutics (NASDAQ: ONTX) at Buy with a price target of $6 following Q2 results and update issued Monday.

Analyst Jason McCarthy noted the following key points today:

Onconova reported 2Q16 with revenues of $2.2M and a... More